Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Kirby Institute

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: Private

Established: 1986-01-01

Employees: 101

Market Cap: -

Website: https://kirby.unsw.edu.au

Clinical Trials

Maraviroc Switch Collaborative Study

Phase 4

Completed

Conditions: HIV

Interventions: Drug: Maraviroc

First Posted Date: 2011-06-29

Last Posted Date: 2016-01-20

Lead Sponsor: Kirby Institute

Target Recruit Count: 399

Registration Number: NCT01384682

Locations: 🇦🇷
FUNCEI, Buenos Aires, Ciudad de Buenos Aires, Argentina
🇦🇷
Hospital Italiano de Buenos Aires, Buenos Aires, Ciudad de Buenos Aires, Argentina
🇦🇷
Hospital G de Agudos JM Ramos Mejia, Buenos Aires, Ciudad de Buenos Aires, Argentina

and more 48 locations

A Collaborative Trial in Injectors of Individualized Treatment for Genotype 2/3

Phase 4

Completed

Conditions: Hepatitis C, Chronic

Interventions: Drug: Pegylated interferon alfa 2b
Drug: Ribavirin

First Posted Date: 2011-06-02

Last Posted Date: 2019-11-18

Lead Sponsor: Kirby Institute

Target Recruit Count: 93

Registration Number: NCT01364090

Locations: 🇦🇺
Hunter Pharmacotherapy, Newcastle, New South Wales, Australia
🇦🇺
Nepean Hospital, Penrith, New South Wales, Australia
🇦🇺
St Vincent's Hospital, Sydney, New South Wales, Australia

and more 14 locations

Treatment of Recently Acquired Hepatitis C Virus Infection

Phase 4

Completed

Conditions: Acute Hepatitis C

Interventions: Drug: Peginterferon alfa-2a
Drug: Ribavirin

First Posted Date: 2011-04-15

Last Posted Date: 2015-09-02

Lead Sponsor: Kirby Institute

Target Recruit Count: 82

Registration Number: NCT01336010

Locations: 🇦🇺
Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
🇦🇺
Kirketon Road Centre, Darlinghurst, New South Wales, Australia
🇦🇺
St Vincent's Hospital, Darlinghurst, New South Wales, Australia

and more 5 locations

A Study to Explore Reconstitution of Immunity in Patients With Advanced HIV-1-infection

Completed

Conditions: HIV Immune Restoration

First Posted Date: 2011-02-15

Last Posted Date: 2013-12-18

Lead Sponsor: Kirby Institute

Target Recruit Count: 53

Registration Number: NCT01296373

Locations: 🇹🇭
HIV-NAT, Bangkok, Thailand

The Intensive Pharmacokinetics Sub-study of Encore1 (ENCORE1-PK)

Phase 3

Completed

Conditions: HIV Infection

Interventions: Drug: Efavirenz

First Posted Date: 2011-01-07

Last Posted Date: 2013-05-13

Lead Sponsor: Kirby Institute

Target Recruit Count: 40

Registration Number: NCT01271894

Locations: 🇦🇷
Hospital J.M. Ramos Mejia, Buenos Aires, Argentina
🇿🇦
Desmond Tutu HIV Foundation, Cape Town, South Africa
🇹🇭
Thai Red Cross-AIDS Research Centre, HIV-NAT Research Collaboration, Bangkok, Thailand

and more 1 locations

Safety and Efficacy of Reduced Versus Standard Dose Efavirenz (EFV) Plus Two Nucleotides in Antiretroviral-naïve Adults.

Phase 3

Completed

Conditions: HIV Infections

Interventions: Drug: Efavirenz 600mg
Drug: Efavirenz 400mg

First Posted Date: 2009-11-11

Last Posted Date: 2020-02-21

Lead Sponsor: Kirby Institute

Target Recruit Count: 636

Registration Number: NCT01011413

Locations: 🇦🇺
St Vincent's Hospital, Sydney, New South Wales, Australia

Pharmacokinetics of Lopinavir/Ritonavir at Three Different Doses.

Phase 1

Completed

Conditions: Acquired Immunodeficiency Syndrome

Interventions: Drug: lopinavir/ritonavir

First Posted Date: 2009-09-28

Last Posted Date: 2011-03-29

Lead Sponsor: Kirby Institute

Target Recruit Count: 22

Registration Number: NCT00985543

Locations: 🇬🇧
St Stephen's Centre, Chelsea and Westminster Hospital, London, United Kingdom

Pharmacokinetics of Lamivudine at Two Different Doses

Phase 1

Completed

Conditions: HIV Infections

Interventions: Drug: Lamivudine (3TC)

First Posted Date: 2009-09-28

Last Posted Date: 2011-02-11

Lead Sponsor: Kirby Institute

Target Recruit Count: 24

Registration Number: NCT00985647

Locations: 🇬🇧
St Stephen's Centre, Chelsea and Westminster Hospital, London, United Kingdom

A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen

Phase 4

Completed

Conditions: HIV Infections

Interventions: Drug: 2N(t)RTI
Drug: raltegravir
Drug: Ritonavir-boosted lopinavir

First Posted Date: 2009-07-02

Last Posted Date: 2019-09-04

Lead Sponsor: Kirby Institute

Target Recruit Count: 558

Registration Number: NCT00931463

Locations: 🇦🇷
Hospital Interzonal General de Agudos, Oscar Alende, Buenos Aires, Mar Del Plata Provincia, Argentina
🇦🇷
CAICI, Buenos Aires, Rosario Provincia De Sante Fe, Argentina
🇦🇷
Hospital General de Agudos 'Teodoro Alvarez', Buenos Aires, Argentina

and more 41 locations

Raltegravir and Atazanavir Dosing Strategy Study

Phase 3

Completed

Conditions: HIV Infection

Interventions: Drug: atazanavir plus raltegravir

First Posted Date: 2009-04-02

Last Posted Date: 2012-04-12

Lead Sponsor: Kirby Institute

Target Recruit Count: 26

Registration Number: NCT00874523

Locations: 🇦🇺
Holdsworth House Medical Practice, Sydney, New South Wales, Australia
🇦🇺
St Vincent's Hospital, Sydney, New South Wales, Australia

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy